CAJ | 학술논문

目的:研究沙利度胺(thalidomide)联合曲安奈德对人脐静脉内皮细胞(HUVEC)的药物作用.方法:Ⅰ型胶原酶消化法原代培养HUVEC, Ⅷ因子相关抗原检测法鉴定细胞.沙利度胺溶于0.5%二甲基亚砜(DMSO)中,分为3组.A组为沙利度胺组,分4个浓度梯度,分别为10、25、50和75 mg/L;B组为沙利度胺+曲安奈德组,为含1 mg/L曲安奈德的各浓度沙利度胺;C组为对照组.HUVEC传代植入96孔板,细胞密度为1×10~4/mL,过夜,加入不同浓度的药物,处理72 h; 在酶标仪570 nm波长处读取吸光度(A)值. 结果: 2组药物均对HUVEC的增殖有明显的抑制作用 (P < 0.01),抑制作用与药物浓度呈正相关;与A组相比,B组对HUVEC抑制作用更强(P < 0.05).结论:沙利度胺及曲安奈德对血管内皮细胞增殖有明显作用,这两类药物在治疗新生血管性疾病中可发挥一定作用.
목적:연구사리도알(thalidomide)연합곡안내덕대인제정맥내피세포(HUVEC)적약물작용.방법:Ⅰ형효원매소화법원대배양HUVEC, Ⅷ인자상관항원검측법감정세포.사리도알용우0.5%이갑기아풍(DMSO)중,분위3조.A조위사리도알조,분4개농도제도,분별위10、25、50화75 mg/L;B조위사리도알+곡안내덕조,위함1 mg/L곡안내덕적각농도사리도알;C조위대조조.HUVEC전대식입96공판,세포밀도위1×10~4/mL,과야,가입불동농도적약물,처리72 h; 재매표의570 nm파장처독취흡광도(A)치. 결과: 2조약물균대HUVEC적증식유명현적억제작용 (P < 0.01),억제작용여약물농도정정상관;여A조상비,B조대HUVEC억제작용경강(P < 0.05).결론:사리도알급곡안내덕대혈관내피세포증식유명현작용,저량류약물재치료신생혈관성질병중가발휘일정작용.
Objective: To investigate the effect of thalidomide and triamcinolone acetonide (TA) on human umbilical vein endothelial cells (HUVEC). Methods: The primary culture of HUVEC with collagenase Ⅰ was identified with FⅧAg. There were 3 groups in the study including thalidomide group(10, 25, 50 and 75 mg/L), TA and thalidomide group and control group. The absorbance ratio was measured through MTT-test. Results: Both thalidomide group and TA and thalidomide group showed inhibitor effect on the growth of HUVEC significantly(P < 0.01). The inhibitory effect was dose dependent. Compared to thalidomide group, the inhibitory effect was more significant in TA and thalidomide group(P < 0.05). Conclusion: Thalidomide can inhibit the growth of HUVEC; however, the effect was more significant in TA and thalidomide group.